innerbuddies gut microbiome testing

Gut Microbiome in Type 1 Diabetes: Early Signs in At-Risk Individuals & Prevention

For individuals who are preclinical or at risk for type 1 diabetes (T1D), the gut microbiome is increasingly recognized as a meaningful “early warning system” and potential lever for prevention. Before classic symptoms appear, immune changes linked to autoimmunity can be accompanied by measurable shifts in gut microbial communities—such as reduced microbial diversity, altered metabolite profiles, and changes in bacteria that influence gut barrier function and immune signaling.

Research suggests the microbiome may affect T1D risk through multiple pathways: regulation of inflammation, maturation of immune tolerance, maintenance of intestinal barrier integrity, and production of metabolites (for example, short-chain fatty acids) that help train immune cells toward balance rather than attack. In at-risk groups—such as relatives of people with T1D or individuals with islet autoantibodies—these microbial patterns may emerge years before diagnosis, offering a window to understand early biology and potentially intervene.

The good news: evidence-based prevention strategies can be microbiome-relevant. Diet quality (including adequate fiber and plant diversity), maintaining healthy weight, limiting unnecessary ultra-processed foods, supporting regular physical activity, and considering gut-friendly habits that promote microbial resilience may help foster a gut environment that supports immune homeostasis. While microbiome testing and “gut supplements” are not universal solutions, targeting modifiable lifestyle factors offers a practical, low-risk approach that aligns with the growing goal of reducing T1D progression from preclinical stages.

Order Your Gut Microbiome Test for At-Risk T1D Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Preclinical / at-risk T1D

Type 1 diabetes (T1D) begins in the preclinical/at-risk phase when autoimmunity may be developing without symptoms, identified by islet autoantibodies and dysregulated glucose. The gut microbiome is emerging as a key environmental factor shaping immune maturation; early microbial shifts—often reduced diversity and altered short-chain fatty acid–producing taxa—may help explain why some individuals progress to clinical T1D while others remain stable, even though signatures are not diagnostic on their own.

Mechanistic links center on short-chain fatty acids, especially butyrate, which support regulatory T cells and strengthen gut barrier function to limit inflammatory signals. Other pathways include bile acid signaling via FXR/TGR5 and microbe-associated molecular patterns (MAMPs) that influence immune tone, with life-course factors like antibiotics perturbing microbiome ecology and potentially miscalibrating immune education.

Testing the gut microbiome provides functional insight beyond who is present, helping to interpret risk trajectories and tailor prevention. Evidence-based strategies emphasize higher dietary fiber and plant diversity to boost SCFA production and barrier health, along with careful antibiotic use. Tools like InnerBuddies translate microbiome function into a mechanism-based readout, enabling longitudinal tracking and informing personalized prevention alongside standard immune monitoring.

  • Loss of butyrate-producing taxa (Faecalibacterium prausnitzii, Roseburia spp., Anaerostipes spp., Butyrivibrio spp., Subdoligranulum spp.) reduces butyrate-driven Treg induction and weakens gut barrier, increasing autoimmunity risk in preclinical T1D.
  • Expansion of pro-inflammatory taxa (Bacteroides fragilis group, Collinsella, Escherichia–Shigella, Enterococcus, Streptococcus, Ruminococcus gnavus group) is linked to a more inflammatory immune tone during the preclinical window.
  • Reduced microbial diversity and altered carbohydrate fermentation pathways lead to lower SCFA availability and disrupted immune signaling.
  • Altered bile acid metabolism due to microbiome shifts (changes in primary to secondary bile acids) modulates FXR/TGR5 signaling and inflammatory tone, influencing immune differentiation.
  • Shifts in microbial patterns of MAMPs affect antigen presentation and cytokine signaling, biasing toward autoimmunity.
  • Disrupted gut barrier integrity from microbiome changes increases exposure to inflammatory microbial products reaching the systemic immune system.
  • Early-life antibiotic exposure and environmental factors can miscalibrate immune education, increasing progression risk from autoimmunity to clinical T1D.
Order Your Gut Microbiome Test for At-Risk T1D Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Type 1 diabetes (T1D)

Type 1 diabetes (T1D) is an autoimmune disease in which the immune system targets pancreatic beta cells, leading to insulin deficiency. In the preclinical/at-risk phase, autoimmunity may be developing without symptoms—often identified through biomarkers such as multiple pancreatic autoantibodies and measures of dysregulated glucose metabolism. Because immune maturation is influenced by the gut and environmental exposures, the gut microbiome has emerged as a promising area of research for understanding why some individuals progress from risk to clinical disease while others do not.

Early changes in the gut microbiome can affect immune balance through multiple pathways, including short-chain fatty acid (SCFA) production (e.g., butyrate), gut barrier integrity, and modulation of inflammation and immune cell behavior (such as regulatory T cells). Several studies suggest that at-risk individuals may show characteristic microbial shifts—sometimes involving reduced diversity, altered abundance of SCFA-producing taxa, and changes in pathways related to carbohydrate fermentation or bile acid metabolism. These microbiome signatures are not diagnostic on their own, but they may help explain early immune dysregulation and offer clues about which interventions could help preserve tolerance.

For prevention in at-risk T1D, evidence-based strategies are increasingly focused on reducing immune stressors while supporting beneficial microbial functions. Diet patterns that support microbial diversity—such as higher fiber intake and a varied intake of plant-based foods—may encourage SCFA production and strengthen barrier health. Lifestyle factors (including appropriate body weight, physical activity, and avoidance of unnecessary antibiotics when possible) can also shape microbial ecology. In research settings, scientists are exploring whether targeted approaches—such as personalized nutrition, probiotic/prebiotic strategies, and other gut-directed therapies—can shift the microbiome toward a more anti-inflammatory profile and potentially lower the likelihood of progression to clinical T1D, especially when implemented early.

  • Frequent urination (especially at night) and increased thirst
  • Unintentional weight loss despite normal or increased appetite
  • Unusual fatigue, weakness, or decreased energy
  • Blurred vision (often from blood sugar fluctuations)
  • Increased hunger (polyphagia)
  • Recurrent yeast infections or slow-healing skin infections
Order Your Gut Microbiome Test for At-Risk T1D Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Preclinical / at-risk T1D

This content is most relevant for people who are in the preclinical or “at-risk” stage of type 1 diabetes, meaning they don’t yet have classic symptoms but may have evidence of developing autoimmunity—such as multiple pancreatic autoantibodies and/or subtle abnormalities in glucose regulation. It’s also relevant for families and clinicians involved in monitoring individuals over time to identify early immune dysregulation and study how early gut microbial patterns may relate to progression.

It’s particularly useful for those who are interested in understanding how gut microbiome changes could influence immune balance before clinical T1D begins. The research focus includes microbial shifts seen in some at-risk individuals—often involving differences in microbial diversity and in bacteria linked to short-chain fatty acid (SCFA) production (like butyrate), as well as pathways related to carbohydrate fermentation and bile acid metabolism. These gut functions can affect gut barrier integrity, inflammation, and immune cell behavior (including regulatory T cells), which may help explain why some people progress while others remain stable.

The information may also resonate for individuals who want early prevention strategies that could reduce immune stressors and support beneficial microbial activity—especially during the window before symptoms such as frequent urination, increased thirst, unexplained weight loss, fatigue, or recurrent infections appear. While the microbiome is not a stand-alone diagnostic tool, it can guide interest in evidence-based lifestyle and nutrition approaches (e.g., higher fiber, varied plant intake, and minimizing unnecessary antibiotics) and ongoing research into targeted gut-directed therapies that aim to promote an anti-inflammatory microbial profile.

Type 1 diabetes (T1D) is relatively uncommon in the general population compared with type 2 diabetes, but the “preclinical/at-risk” stage is much more prevalent than clinically diagnosed disease. In practice, many individuals progress from immune autoimmunity to symptomatic T1D through a period where they may have multiple pancreatic islet autoantibodies and dysregulated glucose metabolism but no classic symptoms yet. Because this at-risk phase is identified through screening and biomarkers rather than symptoms, population prevalence estimates vary by age, geography, and screening criteria.

Across populations, T1D autoimmunity is detected in a meaningful minority of children and relatives of people with T1D, and the risk of eventual clinical T1D is higher in those groups. Among first-degree relatives of individuals with T1D—especially children—multiple islet autoantibodies are the clearest marker of progressing toward clinical disease, and a substantial fraction of those with multiple autoantibodies will develop symptomatic T1D over subsequent years. By contrast, in the general population, the proportion who reach a confirmed “multiple autoantibody” stage is lower, so prevalence estimates for the at-risk condition depend heavily on whether studies include family-based enrichment and how they define “at-risk” (e.g., single vs. multiple autoantibodies, age at screening, and presence of dysglycemia).

Symptoms like frequent urination, increased thirst, weight loss, fatigue, blurred vision, polyphagia, and recurrent infections typically occur later—when insulin deficiency is established—so they are not reliable indicators of preclinical/at-risk T1D prevalence. Instead, prevalence of the preclinical stage is best understood through screening cohorts: the share of people who harbor islet autoimmunity and metabolic dysregulation is typically several-fold higher in children and in first-degree relatives than in the overall population. This is why gut microbiome research often focuses on early, biomarker-defined stages—microbiome differences (e.g., reduced diversity and altered SCFA-associated functions) may appear before symptoms, potentially contributing to early immune imbalance even when clinical prevalence is still “silent.”

Order Your Gut Microbiome Test for At-Risk T1D Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and Type 1 Diabetes: Early Signs, At-Risk Individuals & Prevention

In preclinical/at-risk T1D, the immune system may be developing autoimmunity before symptoms appear, and the gut microbiome is increasingly viewed as a contributor to this early immune “miscalibration.” Microbial communities can influence immune tolerance through short-chain fatty acid (SCFA) production (especially butyrate), which supports regulatory immune pathways such as regulatory T cells, and through effects on gut barrier integrity that help limit inflammatory signals reaching the immune system.

Because immune maturation is shaped by environmental exposures—including diet and infections that alter microbiome ecology—at-risk individuals may show early microbial shifts that affect immune balance. Research has reported patterns such as reduced microbial diversity, altered abundance of SCFA-producing taxa, and changes in pathways involved in carbohydrate fermentation and bile acid metabolism. These functional differences may promote a more pro-inflammatory milieu or weaken protective mechanisms, potentially increasing the likelihood that immune dysregulation progresses toward clinical T1D.

While gut microbiome signatures alone aren’t diagnostic, they may help explain why some people remain stable while others progress. Prevention-focused strategies in at-risk T1D often emphasize supporting beneficial microbial functions—commonly via higher dietary fiber and a varied plant-forward intake to promote SCFA production and strengthen barrier health—along with minimizing unnecessary antibiotic disruption when possible. As the disease advances, symptoms such as frequent urination, thirst, fatigue, and weight changes reflect systemic metabolic and immune effects of insulin deficiency, and gut-directed interventions are being studied to shift the microbiome toward a less inflammatory profile that may help preserve tolerance early.

Order Your Gut Microbiome Test for At-Risk T1D Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and Preclinical / at-risk T1D

  • Short-chain fatty acid (SCFA)–mediated immune tolerance: SCFA-producing microbes (notably butyrate) promote regulatory T cell (Treg) development and function, helping keep autoreactive immune responses in check during the preclinical window.
  • Gut barrier integrity and reduced inflammatory signaling: Microbial metabolites and community structure influence epithelial tight junctions and mucus layer stability; a weaker barrier allows greater translocation of microbial products (e.g., LPS) that can stimulate pro-inflammatory immune pathways.
  • Altered bile acid metabolism shaping immune tone: Gut bacteria convert primary to secondary bile acids, which act as signaling molecules (e.g., via FXR/TGR5) to modulate inflammation and immune cell differentiation; dysregulated bile acid profiles may favor autoimmunity.
  • Immune system education via microbial-associated molecular patterns (MAMPs): Changes in microbial composition can shift the types and quantities of MAMPs reaching the immune system, biasing antigen presentation and inflammatory cytokine production.
  • Reduced microbial diversity and loss of protective taxa: At-risk individuals often show reduced diversity and altered abundance of SCFA/beneficial fermenting taxa, weakening resilience against inflammatory triggers and decreasing protective metabolic functions.
  • Carbohydrate fermentation and metabolic pathway shifts: Differences in dietary substrates and microbial fermentation capacity alter metabolite availability (beyond SCFAs), which can influence immune signaling, oxidative stress, and tolerance pathways relevant to disease progression.
  • Antibiotic/early-life perturbations and delayed immune calibration: Disruptions to microbiome ecology (including antibiotics and early environmental exposures) can impair normal immune maturation, increasing the likelihood that immune dysregulation progresses toward clinical T1D.

In preclinical or at-risk type 1 diabetes, the immune system can begin forming autoimmunity before classic symptoms appear, and the gut microbiome is thought to help shape whether immune tolerance is maintained or disrupted. A key mechanism is the production of short-chain fatty acids (SCFAs)—especially butyrate—by fiber-fermenting microbes. SCFAs support regulatory immune pathways by promoting regulatory T cell (Treg) development and function, which helps restrain autoreactive immune activity during early disease windows.

Microbial influence also extends to the gut barrier. The microbiome helps maintain epithelial tight junctions and a stable mucus layer, limiting the leakage of inflammatory microbial products such as LPS into the circulation. When community structure shifts (often alongside reduced diversity and fewer protective, SCFA-producing taxa), barrier integrity can weaken, allowing greater exposure to pro-inflammatory signals that bias the immune system toward an inflammatory state rather than tolerance. In parallel, microbial metabolic activities—particularly carbohydrate fermentation and other pathway changes—can alter the availability of metabolites that affect immune signaling, oxidative stress, and immune equilibrium.

Beyond SCFAs and barrier effects, the gut microbiome can modulate immune tone through bile acid metabolism and microbial-associated molecular patterns (MAMPs). Gut bacteria convert primary to secondary bile acids, which act as signaling molecules (e.g., via FXR/TGR5) to influence inflammation and immune cell differentiation; dysregulated bile acid profiles may therefore tilt the immune response toward autoimmunity. Additionally, changes in the types and quantities of MAMPs reaching the immune system can shift antigen presentation and cytokine signaling. Finally, early-life and antibiotic perturbations can delay or miscalibrate immune education by disrupting microbiome ecology, potentially increasing the likelihood that immune dysregulation progresses from risk to clinical T1D.

Order Your Gut Microbiome Test for At-Risk T1D Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Microbial patterns summary

In preclinical or at-risk type 1 diabetes, studies often describe gut microbiome signatures consistent with early immune “miscalibration,” including reduced overall diversity and shifts in the relative abundance of taxa involved in beneficial metabolic functions. Researchers frequently report alterations in the kinds of organisms that contribute to carbohydrate fermentation and in the pathways that generate protective microbial metabolites, alongside changes in microbial community structure that may correspond with a more inflammatory or less tolerant immune environment. While these signatures are not diagnostic on their own, they can help explain why some individuals progress toward clinical disease while others remain stable.

A recurring mechanistic theme is diminished capacity for short-chain fatty acid (SCFA) production—particularly butyrate—driven by changes in fiber-fermenting microbial communities. SCFAs support regulatory immune pathways, including the development and function of regulatory T cells (Tregs), which are important for restraining autoreactive responses during early disease windows. When SCFA-producing taxa are reduced or when fermentation-related functions are altered, the balance of immune signaling may shift away from tolerance. In parallel, community-level changes can weaken gut barrier integrity, reducing the epithelial and mucus defenses that normally limit inflammatory microbial products from reaching the immune system.

Beyond SCFAs and barrier effects, microbial metabolism of bile acids and the composition of microbial products reaching the gut immune interface can further influence immune tone. Gut bacteria convert primary to secondary bile acids, which act as signaling molecules through receptors such as FXR and TGR5 to modulate inflammation and immune cell differentiation; dysregulated bile acid profiles may therefore favor pro-inflammatory immune signaling. Similarly, altered patterns of microbial-associated molecular patterns (MAMPs) can influence antigen presentation and cytokine production. Early-life exposures and antibiotic perturbations that disrupt microbial ecology may delay or miscalibrate normal immune education, increasing the likelihood that immune dysregulation progresses from risk to overt T1D.


Low beneficial taxa

  • Faecalibacterium prausnitzii (butyrate producer)
  • Roseburia spp. (butyrate-producing fermenters)
  • Anaerostipes spp. (butyrate-producing fermenters)
  • Butyrivibrio spp. (SCFA-producing; fiber/fermentation associated)
  • Bifidobacterium longum group (bifidobacteria; acetate/SCFA-supporting cross-feeding)
  • Subdoligranulum spp. (fiber fermentation; SCFA-linked community members)


Elevated / overrepresented taxa

  • Bacteroides fragilis group (incl. some enterotoxigenic strains associated with pro-inflammatory immune tone)
  • Collinsella (often linked with altered carbohydrate metabolism and inflammatory associations in dysbiosis contexts)
  • Escherichia–Shigella
  • Enterococcus
  • Streptococcus
  • Ruminococcus gnavus group (mucus-associated, often associated with inflammatory phenotypes)


Functional pathways involved

  • Butyrate (SCFA) biosynthesis via fiber fermentation
  • Regulation of regulatory T cell (Treg) differentiation and immune tolerance by SCFAs
  • Glutathione and oxidative stress response (influencing gut epithelial resilience and inflammation)
  • Gut barrier and mucus integrity pathways (including maintenance of epithelial tight junction function)
  • Bile acid metabolism/secondary bile acid formation (FXR/TGR5 signaling modulation)
  • Carbohydrate fermentation pathways (glycan utilization and cross-feeding that support SCFA production)
  • Microbial-associated molecular pattern (MAMP) signaling to innate immunity (e.g., antigen presentation/cytokine induction)
  • Bacterial fermentation of host-derived substrates and mucin degradation (driving pro-inflammatory community shifts)


Diversity note

In preclinical or at-risk type 1 diabetes, gut microbiome studies commonly report reduced overall microbial diversity compared with matched controls. Lower diversity often reflects a less resilient community that may be more easily shifted by diet, infections, or early-life exposures, which can matter during the window when the immune system is calibrating tolerance. Alongside diversity loss, researchers frequently describe a reshaping of community structure, where the balance of taxa associated with beneficial metabolic outputs becomes less favorable, potentially weakening immune-regulatory signals.

Functionally, reduced diversity in at-risk T1D is often accompanied by diminished capacity for fiber fermentation and lower production of short-chain fatty acids (SCFAs), especially butyrate. Because SCFAs help support regulatory immune pathways (including regulatory T cells), a microbiome that is less diverse and less metabolically geared toward SCFA generation may tilt immune tone away from tolerance. This shift can coincide with changes in the types of carbohydrate-fermenting organisms present, altering the metabolites that normally signal a more anti-inflammatory environment.

In addition, diversity-related community changes can coincide with impaired gut barrier protection, which may allow more inflammatory microbial products to interact with the gut immune system. When the microbial community is altered—sometimes after antibiotic perturbations or other ecological disruptions—signals such as microbial-associated molecular patterns (MAMPs) and metabolite signaling (including bile acid transformations) may also change. Together with overall diversity loss, these ecosystem-level shifts can create conditions that favor ongoing immune miscalibration rather than stability, even though microbiome diversity patterns alone are not diagnostic.


Order Your Gut Microbiome Test for At-Risk T1D Get Your Gut Microbiome Test Subscription

Why generic solutions fail

  • Issue with generic solutions

    Generic gut-focused interventions often fail in preclinical/at-risk T1D because this stage is defined by immune “miscalibration” rather than established disease, and the microbiome signals that matter are functional—not just taxonomic. Many broad approaches (e.g., adding a single supplement, boosting probiotics without matching strains/functions, or using one-size-fits-all prebiotics) may not reliably restore the specific metabolic outputs that support immune tolerance, particularly SCFA production like butyrate and the fermentation capacity behind it. If an intervention doesn’t meaningfully improve fiber-fermenting pathways and SCFA availability in the gut, immune regulatory circuits (such as Treg development and function) may not shift in the direction needed to preserve tolerance.

    They also fail when they ignore baseline heterogeneity in what’s driving risk in each individual. At-risk T1D microbiomes can differ in diversity, barrier-related signatures, bile acid metabolism, and the composition of microbial products that interact with the gut immune interface. A generic strategy may improve one feature (like overall diversity) while leaving other tolerance-relevant pathways—such as bile acid conversion that modulates FXR/TGR5 immune signaling, or mucus/epithelial barrier integrity that controls how inflammatory microbial signals reach the immune system—largely unchanged. In that case, the intervention is unlikely to produce the coordinated ecological shift required to dampen pro-inflammatory immune tone.

    Finally, many “generic” solutions inadvertently create disruption rather than protection. Preclinical/at-risk windows are sensitive to timing and ecological stability, so blanket antibiotic use, aggressive dietary restriction, or abrupt microbiome perturbations can further destabilize community functions that are already borderline. Without personalization around diet composition (e.g., fiber quality and fermentability), exposure history (including antibiotics and infections), and the individual’s existing microbial metabolic capacity, interventions may not sustain the tolerance-supporting microbial ecosystem long enough to matter. The result is that general recommendations may look biologically plausible but fail to generate the targeted, durable functional changes linked to preserving immune balance.

  • Common mistakes

    • Treating preclinical/at-risk T1D as a “microbiome missing-nutrients” problem and relying on broad, taxon-level normalization (e.g., chasing diversity) rather than restoring tolerance-relevant microbial functions—especially SCFA (butyrate) production and fiber-fermenting capacity.
    • Using one-size-fits-all probiotics or supplements without matching strains to the patient’s baseline ecology and metabolic deficits (e.g., adding organisms that don’t effectively increase fermentation pathways or butyrate output).
    • Employing generic prebiotics without accounting for fiber quality/fermentability and individual baseline fermentation metabolism, leading to improved general fermentation signals but not the specific functional metabolites that support Treg development/function.
    • Neglecting gut barrier and mucus/epithelial integrity signals; focusing only on “good bugs” while ignoring that barrier weakening can allow pro-inflammatory microbial products to reach the immune interface.
    • Failing to consider bile acid metabolism (primary↔secondary conversion) and downstream FXR/TGR5 immune signaling, so interventions may leave immune tone biased toward inflammation despite partial microbiome shifts.
    • Ignoring individual heterogeneity in what drives risk (e.g., some patients may be more sensitive to SCFA deficits, others to bile acid dysregulation or barrier-related patterns), resulting in incomplete or uncoordinated ecological changes.
    • Overlooking timing and ecological stability in a sensitive at-risk window—using abrupt dietary changes, unnecessary antibiotic exposure, or aggressive perturbations that further destabilize already borderline functional outputs.
    • Evaluating success with proxy markers (e.g., short-term diversity or relative abundance changes) rather than functional/host-relevant endpoints tied to immune tolerance (SCFAs, barrier function, bile acid profiles, Treg-associated pathways).

What to do

  • General support strategies

    In preclinical or at-risk type 1 diabetes (T1D), prevention efforts often focus on supporting a gut ecosystem that promotes immune tolerance rather than chronic inflammation. A key strategy is encouraging higher intake of dietary fiber and diverse, plant-forward foods to foster microbial functions linked to protective metabolites—particularly short-chain fatty acids (SCFAs) like butyrate. SCFAs help support regulatory immune pathways (including regulatory T cells) and can contribute to more balanced immune signaling during the window when autoimmunity may be developing.

    Another important approach is to protect gut barrier integrity and reduce exposure to inflammatory triggers. Diet can shape microbial metabolites involved in carbohydrate fermentation and bile acid metabolism, which in turn influence how “tight” the gut barrier remains and how much inflammatory stimulation reaches immune tissues. Emphasizing minimally processed foods, adequate fiber, and healthy dietary patterns may help maintain a microbial community that is less likely to produce pro-inflammatory signals and more likely to support mucosal homeostasis.

    Because microbiome ecology is sensitive to disruptions, minimizing unnecessary antibiotic use—when clinically appropriate—is also a common support strategy. Researchers are actively studying whether gut-targeted interventions (such as fiber-focused dietary changes, microbiome-friendly nutrition, and carefully designed prebiotic or probiotic approaches) can shift early microbial patterns toward a less inflammatory profile. These gut-focused steps are not diagnostic on their own, but they may help create environmental conditions that lower the risk that immune dysregulation progresses toward clinical T1D.

  • Lifestyle recommendations

    • Increase dietary fiber with a varied, plant-forward intake (e.g., legumes, whole grains, fruits, vegetables) to support SCFA (including butyrate)–producing microbes.
    • Maintain a diverse diet (multiple plant types and colors) to promote microbiome diversity and more resilient ecosystem function.
    • Limit highly processed foods and excess added sugars, which can shift the gut toward less favorable inflammatory profiles.
    • Prioritize gut-barrier support by including prebiotic foods (e.g., onions, garlic, leeks, bananas/plantains, oats) and fermented foods in tolerated amounts (e.g., yogurt/kefir) to encourage beneficial microbial activity.
    • Use antibiotics only when medically necessary and discuss timing/minimizing disruption with clinicians when possible.
    • Aim for regular physical activity and healthy sleep, as these can influence microbiome composition and immune regulation.

  • Nutrition recommendations

    • Increase dietary fiber to support SCFA production (especially butyrate) using a variety of plant foods (e.g., legumes, oats, whole grains, apples/berries, and cruciferous vegetables).
    • Adopt a plant-forward, microbiome-diverse eating pattern (aim for a wide “rainbow” of produce and mixed plant proteins) to promote microbial diversity and functional resilience.
    • Prioritize prebiotic substrates (inulin/FOS-type fibers, resistant starch) such as chicory root, onions, garlic, leeks, bananas (slightly green), cooked-and-cooled potatoes/rice, and legumes—titrate gradually to tolerance.
    • Limit ultra-processed foods and added sugars, which can disrupt gut barrier function and promote pro-inflammatory metabolic signaling relevant to immune “miscalibration.”
    • Support healthy fat quality by emphasizing olive oil, nuts, seeds, and fatty fish while reducing frequent high-saturated-fat/processed-fat intake to avoid unfavorable bile acid and inflammation pathways.
    • Maintain consistent, adequate protein intake—favoring minimally processed sources (fish, eggs, poultry, legumes, yogurt if tolerated)—and avoid extreme swings that may destabilize microbial ecology.
    • If antibiotics are used, discuss minimizing disruption when appropriate and consider restoring gut-friendly intake afterward (fiber/prebiotics) to help re-establish beneficial communities.

  • Supplement considerations

    In preclinical or at-risk T1D, gut-linked supplement strategies generally aim to support immune tolerance and barrier function before overt dysglycemia emerges. A core concept is promoting microbial metabolic outputs that favor regulatory immune pathways—especially short-chain fatty acid (SCFA) production, with butyrate being a key player. Supplements that increase substrate availability for SCFA-producing microbes (for example, specific fibers that act as prebiotics) are often considered, because they can shift fermentation toward beneficial metabolites and help reduce the risk of an imbalanced, more pro-inflammatory immune tone associated with early dysbiosis.

    Barrier integrity is another practical target in at-risk states. When gut tight junction function is compromised or inflammatory signaling increases, immune “miscalibration” may become more likely. Nutrients and microbiome-modulating compounds that support mucosal health—such as certain non-digestible fibers, SCFA-related interventions (where appropriate), and compounds with anti-inflammatory effects—are sometimes used to reinforce the gut environment that nurtures tolerogenic immune cells. In parallel, supplement plans often account for the ecology of the microbiome: abrupt or unnecessary antimicrobial exposure can disrupt protective communities, so many prevention-focused approaches emphasize microbiome-friendly choices rather than interventions that broadly sterilize gut ecosystems.

    Finally, supplement considerations are usually tailored to functional patterns seen in at-risk cohorts, such as reduced diversity and altered pathways related to carbohydrate fermentation and bile acid metabolism. Rather than relying on one “single magic” product, many evidence-informed strategies focus on consistent, diet-adjacent microbial support (often via targeted prebiotic fibers) and, in some cases, carefully selected probiotic strains—especially those shown to enhance barrier markers and modulate inflammatory signaling in gut-immune contexts. Because immune outcomes in T1D development are complex and heterogeneous, it’s also important to treat supplements as supportive tools that should be integrated with overall nutritional quality, monitoring, and clinician guidance rather than used as stand-alone prevention.

  • Retesting / monitoring note

    In preclinical/at-risk T1D, retesting is typically considered when results are being used to track progression of immune dysregulation or to evaluate whether an intervention (e.g., diet changes, probiotic/prebiotic strategies, or antibiotic avoidance plans) is actually shifting gut ecology toward a more protective profile. Because the gut microbiome can respond quickly to short-term exposures (diet composition, infections, travel, stress, and medication), follow-up sampling is often planned after stabilization of routines rather than immediately after a single “signal” test. Many programs therefore use repeat stool collection at defined intervals—commonly weeks to a few months—so functional readouts such as fiber-fermentation capacity, SCFA-related signatures (e.g., butyrate-associated pathways), and gut barrier–linked markers can be assessed with less noise.

    When retesting for at-risk T1D, consistency in sample handling and metadata collection is important. Standardizing collection kits, storage/transport timing, and dietary reporting (or at least maintaining a stable diet pattern before sampling) helps make longitudinal comparisons meaningful. Retesting can also be timed to coincide with parallel immune monitoring (for example, autoantibody dynamics or immune-relevant blood markers) so microbiome changes can be interpreted in the context of whether tolerance is strengthening or weakening. If a first test suggested reduced microbial diversity or diminished SCFA-producing functional pathways, a subsequent test can help determine whether those functional deficits persist or improve under prevention-focused dietary patterns.

    Finally, retesting recommendations should incorporate clinical practicality and avoid over-interpreting single microbiome snapshots. Because gut microbial signals alone are not diagnostic, repeat testing is most valuable when it is tied to a clear decision point—such as confirming a sustained shift toward higher carbohydrate fermentation and bile-acid–related pathway balance, or verifying that antibiotic exposure has not substantially disrupted protective taxa and functions. If changes are observed but symptoms or immune markers indicate continued progression risk, clinicians and researchers may consider more comprehensive reassessment (including additional immune measures) rather than repeating microbiome testing alone.

The importance of gut microbiome testing

  • Why testing matters

    In preclinical or at-risk type 1 diabetes (T1D), immune autoimmunity can begin well before symptoms appear, and the gut microbiome may be one of the environmental factors shaping how that immune system “learns” tolerance. Gut microbes help regulate immune balance by producing metabolites such as short-chain fatty acids (SCFAs)—especially butyrate—which support regulatory pathways like regulatory T cells, while also reinforcing gut barrier integrity to reduce inflammatory signals that reach the immune system. Because early microbial shifts (for example, reduced diversity or altered abundance of SCFA-producing functions) may correlate with a more pro-inflammatory immune tone, gut microbiome testing can provide actionable insight into whether an at-risk individual’s gut ecology aligns more with immune-supportive versus immune-stressing conditions.

    Testing also matters because it can capture functional patterns, not just names of microbes. For at-risk T1D, research has observed changes that may affect carbohydrate fermentation, SCFA availability, and bile acid metabolism—pathways that influence immune signaling and metabolic stress. By identifying these microbiome functions and potential dysbiosis signatures, clinicians and prevention-focused programs can better interpret individual risk trajectories and tailor interventions (such as increasing dietary fiber and plant diversity to promote beneficial fermentation and barrier support) rather than relying on one-size-fits-all recommendations.

    While microbiome results are not diagnostic by themselves, they can meaningfully complement immune monitoring and risk assessment by helping explain why some individuals remain stable while others progress. Gut testing may also support longitudinal tracking—showing whether dietary or lifestyle changes are shifting the microbiome toward a less inflammatory profile—thereby providing a mechanism-based way to evaluate prevention strategies during the window when immune miscalibration may still be modifiable.

  • How InnerBuddies helps

    In preclinical or at-risk type 1 diabetes, the immune system can start developing autoimmunity long before classic symptoms appear. The InnerBuddies test helps by characterizing the gut microbiome in a way that can reveal whether the gut ecosystem looks more aligned with immune-supportive balance or with conditions that may weaken tolerance. Because gut microbes influence immune “training” through metabolites—particularly short-chain fatty acids (SCFAs) like butyrate—and through effects on intestinal barrier integrity, microbiome patterns can provide clues about whether protective regulatory pathways may be under pressure early in disease development.

    InnerBuddies also helps with interpretation beyond just identifying organisms by focusing on functional tendencies linked to immune signaling. In at-risk T1D, research has reported shifts such as reduced microbial diversity and changes in pathways related to carbohydrate fermentation (which can impact SCFA availability) and bile acid metabolism (which can influence inflammatory tone and metabolic signaling). By mapping these microbiome features, the InnerBuddies result can offer a mechanism-based perspective on why an individual may be progressing differently than others, helping connect gut ecology with immune risk trajectories.

    While a gut microbiome test cannot diagnose or predict T1D on its own, InnerBuddies can add actionable context alongside standard risk monitoring. The results can support prevention-oriented decisions—such as increasing dietary fiber and plant variety to encourage beneficial fermentation and barrier-supporting functions, and avoiding unnecessary antibiotic disruption when feasible. Just as importantly, the test can be used for longitudinal tracking to see whether dietary or lifestyle changes are shifting gut function toward a less inflammatory profile during the critical window when immune miscalibration may still be modifiable.

Medical Evidence

  • Scientific evidence level

    2 [weak: emerging but inconsistent; mostly mechanistic/preclinical and association-level human data without robust prospective prediction or validated clinical utility]

  • Clinical relevance note

    GRADE-like confidence (High/Moderate/Low/Very low): Overall confidence is LOW to VERY LOW. The main reasons are inconsistency across studies, heterogeneity in participants (age, diet, HLA/genetic risk, number/type of autoantibodies), and methodological variability in microbiome measurement/analysis. While mechanistic studies in animals strengthen plausibility, they do not resolve key human issues such as confounding (diet, antibiotic exposure, breastfeeding, socioeconomic factors), reverse causality (early immune dysregulation affecting gut ecology), and stool-versus-mucosa mismatch.

    Current clinical relevance: At present, gut microbiome testing is not a validated tool for preventing, diagnosing, stratifying, or monitoring preclinical/at-risk T1D in routine care. The field is at the stage of biomarker discovery where signatures may correlate with risk status, but there is insufficient evidence of stable, reproducible predictive performance across external cohorts, and no intervention studies have shown that microbiome-targeted therapy changes clinically meaningful outcomes (e.g., prevents progression to type 1 diabetes) with validated microbiome-mediated mechanisms. Consequently, the microbiome is scientifically interesting and potentially contributory to pathogenesis, but not clinically actionable for decision-making in at-risk T1D.

    Distinguishing evidence types explicitly: statistically significant associations have been reported in some cohorts (often with modest effect sizes), probable causal involvement is supported mainly by animal and mechanistic data rather than human causal inference, actionable intervention evidence remains limited and mixed (insufficient RCT strength and consistent endpoints), and validated clinical application is not established. The key limitations include confounding/reverse causality, small or moderately sized cohorts for longitudinal endpoints, batch effects and analytic variability, lack of external validation, and limited alignment between stool microbiome metrics and the relevant immune niches.

Title Journal Year Link
The gut microbiome of healthy children is associated with risk of type 1 diabetes Nature Medicine 2020 View →
A compositional analysis of gut microbiome and risk for type 1 diabetes in the TEDDY study Scientific Reports 2018 View →
Gut Microbiome Features Are Associated With Prediction of Autoimmune Type 1 Diabetes Cell Host & Microbe 2017 View →
Gut microbiota in children at risk for type 1 diabetes: a longitudinal study Diabetes 2017 View →
Diet, Gut Microbiome, and Risk of Type 1 Diabetes in Early Childhood Diabetes Care 2015 View →

Frequently Asked Questions

    ¿Qué significa T1D preclínico/en riesgo?
    Es una fase en la que la autoimmunidad puede estar desarrollándose antes de los síntomas, con marcadores inmunitarios (autoanticuerpos de islotes) o alteraciones tempranas del metabolismo de la glucosa, sin signos de deficiencia de insulina.
    ¿Cómo se determina el riesgo en esta fase?
    Detectando autoanticuerpos de los islotes y cambios tempranos en el metabolismo de la glucosa y otros biomarcadores; la historia familiar también puede aumentar el riesgo.
    ¿Cómo se relaciona el microbioma intestinal con el riesgo de T1D?
    Desviaciones microbianas tempranas pueden influir en el equilibrio inmunitario, la integridad de la barrera intestinal y el metabolismo, afectando la progresión del riesgo a la enfermedad.
    ¿Qué son los SCFA y por qué son importantes?
    Ácidos grasos de cadena corta (SCFA), como el butirato, producidos por bacterias intestinales durante la fermentación de fibra; apoyan vías inmunes reguladoras y la barrera intestinal.
    ¿Una prueba del microbioma puede predecir el T1D?
    No, no es diagnóstica por sí sola, pero puede proporcionar información contextual sobre el riesgo inmunitario y ayudar a orientar la prevención.
    ¿Qué mide la prueba InnerBuddies?
    Caracteriza el microbioma para identificar patrones funcionales relacionados con señales inmunes y la salud de la barrera, no es una prueba de enfermedad.
    ¿Existen estrategias de prevención basadas en el microbioma que estén demostradas?
    Las estrategias buscan reducir el estrés inmunitario y apoyar funciones microbianas beneficiosas, como una dieta rica en fibra y diversa en plantas; el uso de probióticos/prébióticos debe manejarse con precaución. La evidencia está en evolución.
    ¿Qué cambios en la dieta pueden apoyar un intestino saludable en at‑risk T1D?
    Una mayor ingesta de fibra y diversidad de plantas para promover la producción de SCFA y el soporte de la barrera; evitar antibióticos innecesarios cuando sea posible.
    ¿Debo evitar los antibióticos para proteger mi microbioma?
    Evita el uso innecesario de antibióticos; consulta a un profesional de la salud sobre riesgos y alternativas cuando sea posible.
    ¿Qué patrones microbianos precoces se observan con frecuencia en T1D en riesgo?
    Menor diversidad y cambios en bacterias productoras de SCFA; cambios en rutas de fermentación de carbohidratos y metabolismo de ácidos biliares.
    ¿Existen síntomas en la fase preclínica?
    La sed, la micción frecuente, la pérdida de peso y la fatiga normalmente aparecen después del desarrollo de deficiencia de insulina; en la fase preclínica no son típicos.
    ¿Cómo aborda la investigación de prevención las terapias dirigidas al microbioma?
    Se explora nutrición personalizada, probióticos/prébioticos y otros enfoques dirigidos al microbioma para reducir la inflamación.
    Si tengo varios autoanticuerpos, ¿qué significa para mi riesgo?
    Entre familiares y ciertos grupos, múltiples autoanticuerpos son un marcador más claro de progresión hacia T1D clínica; no todos con autoanticuerpos desarrollan la enfermedad; depende de la edad y el contexto.
    ¿Cómo deben usarse los resultados de las pruebas del microbioma en la gestión del riesgo?
    Como parte de una evaluación de riesgo más amplia, junto con el monitoreo inmunológico; pueden guiar cambios en el estilo de vida (más fibra, uso cuidadoso de antibióticos) y pueden seguirse a lo largo del tiempo bajo supervisión clínica.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -